Ann: New CEO Appointed - Dr Paul Mastoridis, page-9

So the Board felt that what ADR needs is a US based CEO (they got that one right), big pharma guy used to big pharma teams, resources and dollars , who's skill set is to invent more tech with no experience of commercialising it, no apparent sales,marketing, reimbursement experience nearer end than the beginning of a successful career with previous roles that may have had no interaction with investors. Be good to know what gave him the passion and drive to take on ADR at this point in time. How successful is Novartis in commercialising their offering ?

I wish him all the best as we know this is not an easy ride.

The Board has missed an opportuntiy here to take a bit of a risk and do something different with someone who is trying to make his or her name for the first time and willing to work 24/7/365 on a remuneration package which is highly incentivised, cant afford to fail and could make them serious cash if they suceed. Only hungry cats hunt. As we found with th incumbent, if a cat ain't hungry, it sleeps with contentment.

Time will tell. Lets give the guy every opportunity to do what no one else has done, find the key to commercialsiation.
His first priorities, what is the story he sees that made him take the role get more reimbursed US sales, get peer advocates and then he can get more cash. And you only have a quarter to do it in. All the best